Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed Feb 14, 2025 · 10-Q · 45 days after period end · 0001493152-25-006697
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$430.18K | -$584.38K | -$485.42K | -$799.98K |
| EPS Diluted | -$32.23 | -$1,559.55 | -$0.53 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Dec 31, 2024 · filed Feb 14, 2025 · 45 d after period end
